США - англійська - NLM (National Library of Medicine)

cardinal health - misoprostol (unii: 0e43v0bb57) (misoprostol - unii:0e43v0bb57) - misoprostol 100 ug

США - англійська - NLM (National Library of Medicine)

pfizer laboratories div pfizer inc - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1), misoprostol (unii: 0e43v0bb57) (misoprostol - unii:0e43v0bb57) - diclofenac sodium 50 mg - arthrotec is indicated for treatment of the signs and symptoms of osteoarthritis or rheumatoid arthritis in adult patients at high risk of developing nsaid-induced gastric and duodenal ulcers and their complications. for a list of factors that may increase the risk of nsaid-induced gastric and duodenal ulcers and their complications [see warnings and precautions (5.3)] . arthrotec is contraindicated in the following patients: risk summary arthrotec is contraindicated in pregnant women [see contraindications (4)]. if a woman becomes pregnant while taking arthrotec, discontinue the drug and advise the woman of the potential risks to her and to a fetus. there are no adequate and well-controlled studies of arthrotec in pregnant women; however, there is information available about the active drug components of arthrotec, diclofenac sodium and misoprostol. administration of misoprostol to pregnant women can cause uterine rupture, abortion, premature birth, or birth defects [see warnings and precautions (5.1)] . co

США - англійська - NLM (National Library of Medicine)

bluebay shandong co.,ltd - misoprostol (unii: 0e43v0bb57) (misoprostol - unii:0e43v0bb57) -

США - англійська - NLM (National Library of Medicine)

nanjing chemlin biomedical science & technology co, ltd. - misoprostol (unii: 0e43v0bb57) (misoprostol - unii:0e43v0bb57) -

США - англійська - NLM (National Library of Medicine)

shanghai chemlin biopharm co., ltd. - misoprostol (unii: 0e43v0bb57) (misoprostol - unii:0e43v0bb57) -

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

ms health pty ltd - misoprostol, quantity: 200 microgram - tablet - excipient ingredients: hypromellose; microcrystalline cellulose; sodium starch glycollate; hydrogenated castor oil - gymiso is indicated in females of childbearing age for the medical termination of a developing intrauterine pregnancy in sequential combination with a mifepristone 200 mg tablet, up to 49 days of gestation.

США - англійська - NLM (National Library of Medicine)

bryant ranch prepack - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1), misoprostol (unii: 0e43v0bb57) (misoprostol - unii:0e43v0bb57) - diclofenac sodium 75 mg - diclofenac sodium and misoprostol delayed-release tablets are indicated for treatment of the signs and symptoms of osteoarthritis or rheumatoid arthritis in patients at high risk of developing nsaid-induced gastric and duodenal ulcers and their complications. for a list of factors that may increase the risk of nsaid-induced gastric and duodenal ulcers and their complications [see warnings and precautions (5.2) ]. diclofenac sodium and misoprostol tablets are contraindicated in the following patients: ● known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac sodium and misoprostol, other prostaglandins, or any components of the drug product [see warnings and precautions ( 5.7 , 5.9 )] ● history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [see warnings and precautions ( 5.7 , 5.8 )] ● in the setting of coronary artery bypas

США - англійська - NLM (National Library of Medicine)

bryant ranch prepack - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1), misoprostol (unii: 0e43v0bb57) (misoprostol - unii:0e43v0bb57) - diclofenac sodium and misoprostol delayed-release tablets are indicated for treatment of the signs and symptoms of osteoarthritis or rheumatoid arthritis in patients at high risk of developing nsaid-induced gastric and duodenal ulcers and their complications. for a list of factors that may increase the risk of nsaid-induced gastric and duodenal ulcers and their complications [see warnings and precautions (5.2)] . diclofenac sodium and misoprostol delayed-release tablets are contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac sodium and misoprostol, other prostaglandins, or any components of the drug product [see warnings and precautions (5.7, 5.9)] - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [see warnings and precautions (5.7, 5.8)] - in the setting of coronary artery bypa

США - англійська - NLM (National Library of Medicine)

a-s medication solutions - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1), misoprostol (unii: 0e43v0bb57) (misoprostol - unii:0e43v0bb57) - diclofenac sodium and misoprostol delayed-release tablets are indicated for treatment of the signs and symptoms of osteoarthritis or rheumatoid arthritis in patients at high risk of developing nsaid-induced gastric and duodenal ulcers and their complications. for a list of factors that may increase the risk of nsaid-induced gastric and duodenal ulcers and their complications [see warnings and precautions (5.2)] . diclofenac sodium and misoprostol delayed-release tablets are contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac sodium and misoprostol, other prostaglandins, or any components of the drug product [see warnings and precautions (5.7, 5.9)] - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [see warnings and precautions (5.7, 5.8)] - in the setting of coronary artery bypa

США - англійська - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - misoprostol (unii: 0e43v0bb57) (misoprostol - unii:0e43v0bb57) - mifepristone tablets, 200 mg is indicated, in a regimen with misoprostol, for the medical termination of intrauterine pregnancy through 70 days gestation. - administration of mifepristone tablets, 200 mg and misoprostol for the termination of pregnancy (the “treatment procedure”) is contraindicated in patients with any of the following conditions: confirmed or suspected ectopic pregnancy or undiagnosed adnexal mass (the treatment procedure will not be effective to terminate an ectopic pregnancy) [ see warnings and precautions ( 5.4)] chronic adrenal failure (risk of acute adrenal insufficiency) concurrent long-term corticosteroid therapy (risk of acute adrenal insufficiency) history of allergy to mifepristone, misoprostol, or other prostaglandins (allergic reactions including anaphylaxis, angioedema, rash, hives, and itching have been reported [ see adverse reactions (